The beads were then washed twice with 0.2 M phosphate buffer for 3 min Rabbit polyclonal to Transmembrane protein 57 and the bound proteins eluted by incubation with 500 l of 2 M NaI for 15 min at RT. excised for peptide mass mapping. == Results == Three of the scAbs recognised GnSAF bioactivity and subsequently one clone of the purified scAb-derived immunoglobulin exhibited high affinity for GnSAF bioactivity, also binding the molecule in such as way as to block its bioactivity. When used for repeated immunopurification cycles and then Western blot, this antibody enabled the isolation of a GnSAF-bioactive protein band at around 66 kDa. Similar results were achieved using the rat anti-GnSAF polyclonal antiserum. The main candidate molecules identified from the immunopurified material by excision of 2-D gel protein spots was human serum albumin precursor and variants. == Conclusion == This study demonstrates that this combination of bioassay and phage display technologies is a powerful tool in the study of uncharacterised proteins that defy conventional approaches. In addition, we conclude that these data support suggestions that GnSAF may be structurally related to serum albumin or very tightly bound to serum albumin. == Background == Phage display has proven to be a powerful tool for selecting proteins and peptides with specific binding properties from vast numbers of variants. Phage display is based on the simple fact that if gene fragments encoding polypeptides are fused to bacteriophage M13 coat protein genes, the protein products of these fusion genes are displayed on the surface of the filamentous phage. Studies had shown that functional antibody fragments can be expressed in the periplasmic space ofE. coli[1,2]. In the case of antibodies, antibody fragments are displayed on the surface with the antigen-binding domains exposed to the outside environment. These phage-bearing particles can be bio-panned against immobilised antigen and those that bind can be eluted and used to infect a newE. colipopulation. This process can be repeated several times using lower concentrations of antigen SCH 563705 each time, thus leading to significant enrichment of high affinity antigen-binding phage. The surface antibody fragments can then be sub-cloned intoE. colivectors that produce soluble antibodies which can be manipulated in the same way as any other recombinant protein. Although five putative gonadotrophin surge-attenuating factor (GnSAF) amino acid sequences have been published [3-6], they have no significant homology, were derived from proteins between 1269 kDa in mass, and have not been conclusively confirmed as GnSAF [7]. The purification of GnSAF using conventional chromatographic methods has been fraught with problems, including low concentrations of GnSAF protein in biological fluids despite high bioactivity, co-elution of GnSAF with serum SCH 563705 albumin and the interference from large number of proteins in follicular fluid, serum and cell-conditioned medium [6,8,9]. These difficulties have hampered advances in the field. The production of specific GnSAF antibodies by conventional means has not been successful. The rat pAb reported by [6] reflects this problem, having good affinity for GnSAF bioactivity, but co-purifying inadequate amounts of protein, which are also contaminated with too many other proteins, to allow the production of homogenous GnSAF preparations. Since conventional protein purification and polyclonal antibody strategies have failed to yield conclusive GnSAF candidate molecules, a strategy of combining phage display with our well-established rat pituitary cell bioassay for GnSAF [6,7] was developed. The rationale for this is as follows: Firstly, phage display will produce a range of antibodies to proteins even in the absence of prior purification of the proteins. Secondly, the GnSAF bioassay can be as easily used to detect the absence of GnSAF bioactivity as its presence. Thus, the bioassay could be utilised to pick out phage-derived antibodies that recognised bioactive GnSAF. Once a GnSAF-specific antibody was identified, it could be utilised in an immunopurification strategy to isolate the GnSAF molecule. The current study was therefore devised specifically to SCH 563705 utilise the novel combination of SCH 563705 phage display and SCH 563705 bioassay in order to attempt to identify human ovarian GnSAF. The rationale for the degree of effort that has been invested into GnSAF research revolves around its potential role in the unfavorable regulation of pituitary responsiveness to GnRH [7]. GnSAF probably coordinates the LH signal with ovarian steroidogenesis and follicular development and, as such, would have considerable therapeutic and diagnostic potential for women and commercially important species. == Methods == == GnSAF Bioactive Material and.
The beads were then washed twice with 0
